Cite
Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2021;doi: 10.1016/j.jaad.2021.05.075.
Blauvelt, A., Silverberg, J. I., Lynde, C. W., Bieber, T., Eisman, S., Zdybski, J., Gubelin, W., Simpson, E. L., Valenzuela, F., Criado, P. R., Lebwohl, M. G., Feeney, C., Khan, T., Biswas, P., DiBonaventura, M., Valdez, H., Cameron, M. C., & Rojo, R. (2021). Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. Journal of the American Academy of Dermatology, . https://doi.org/10.1016/j.jaad.2021.05.075
Blauvelt, Andrew, et al. "Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial." Journal of the American Academy of Dermatology vol. (2021). doi: https://doi.org/10.1016/j.jaad.2021.05.075
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, Gubelin W, Simpson EL, Valenzuela F, Criado PR, Lebwohl MG, Feeney C, Khan T, Biswas P, DiBonaventura M, Valdez H, Cameron MC, Rojo R. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2021 Aug 17; doi: 10.1016/j.jaad.2021.05.075. Epub 2021 Aug 17. PMID: 34416294.
Copy
Download .nbib